\n 美国medchemexpress（MCE)浙江省一级代理:杭州昊鑫生物科技股份有限公司美国medchemexpress（MCE)浙江省一级代理:杭州昊鑫生物科技股份有限公司美国medchemexpress（MCE)浙江省一级代理:杭州昊鑫生物科技股份有限公司

Icaritin (Anhydroicaritin) 是\xa0Epimedium Genusis\xa0的异\xa0 \xa0戊\xa0 二\xa0 烯类黄酮衍生物，有效抑制 K562 细胞 (IC₅₀\xa0为 8 μM) 和原代 CML 细胞 (对 CML-CP 的\xa0IC₅₀\xa0值为 13.4 μM，对 CML-BC 的\xa0IC₅₀\xa0值为 18 μM) 的增殖。Icaritin 可以调节\xa0MAPK/ERK/JNK\xa0和\xa0JAK2/STAT3/AKT\xa0信号传导，并具有增强成骨的作用。Icaritin (Anhydroicaritin) 是\xa0Epimedium Genusis\xa0的异\xa0 \xa0戊\xa0 二\xa0 烯类黄酮衍生物，有效抑制 K562 细胞 (IC₅₀\xa0为 8 μM) 和原代 CML 细胞 (对 CML-CP 的\xa0IC₅₀\xa0值为 13.4 μM，对 CML-BC 的\xa0IC₅₀\xa0值为 18 μM) 的增殖。Icaritin 可以调节\xa0MAPK/ERK/JNK\xa0和\xa0JAK2/STAT3/AKT\xa0信号传导，并具有增强成骨的作用。Icaritin (Anhydroicaritin) 是\xa0Epimedium GenusisEpimedium Genusis\xa0的异\xa0 \xa0戊\xa0 二\xa0 烯类黄酮衍生物，有效抑制 K562 细胞 (IC₅₀IC₅₀50\xa0为 8 μM) 和原代 CML 细胞 (对 CML-CP 的\xa0IC₅₀IC₅₀50\xa0值为 13.4 μM，对 CML-BC 的\xa0IC₅₀IC₅₀50\xa0值为 18 μM) 的增殖。Icaritin 可以调节\xa0MAPK/ERK/JNKMAPK/ERK/JNK\xa0和\xa0JAK2/STAT3/AKTJAK2/STAT3/AKT\xa0信号传导，并具有增强成骨的作用。


\xa0

\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

储存方式

\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t Powder -20°C 3 years \xa0 4°C 2 years In solvent -80°C 6 months \xa0 -20°C 1 month \t\t\t

溶解性数据

In Vitro:\xa0\t\t\t DMSO : 15.62 mg/mL\xa0(42.40 mM;\xa0Need ultrasonic) \t\t\t H2O : < 0.1 mg/mL\xa0(insoluble) \t\t\t \t\t\t配制储备液\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t 浓度溶剂体积质量 1 mg 5 mg 10 mg \t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t 1 mM 2.7146 mL 13.5729 mL 27.1459 mL 5 mM 0.5429 mL 2.7146 mL 5.4292 mL 10 mM 0.2715 mL 1.3573 mL 2.7146 mL \t\t\t \t\t\t*\t\t\t 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 \t\t\t储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 \t\t\t \t\t\tIn Vivo:\t\t\t 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照\xa0In Vitro\xa0方式配制澄清的储备液，再依次添加助溶剂： \t\t\t ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百 \t\t\t分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 \t\t\t \t\t\t\t 1.\t\t\t\t 请依序添加每种溶剂：\xa010% DMSO \xa0\xa0 40%\xa0PEG300\xa0\xa0\xa0 5%\xa0Tween-80\xa0\xa0\xa0 45% saline \t\t\t\t Solubility: ≥ 1.56 mg/mL (4.23 mM); Clear solution \t\t\t\t \xa0 \t\t\t\t \t\t\t\t 2.\t\t\t\t 请依序添加每种溶剂：\xa050%\xa0PEG300\xa0\xa0\xa0 50% saline \t\t\t\t Solubility: 1.51 mg/mL (4.10 mM); Suspended solution; Need ultrasonic \t\t\t\t \t\t\t \t\t\t

\t\t\t\t\t\t储存方式\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

Powder	-20°C	3 years
\xa0	4°C	2 years
In solvent	-80°C	6 months
\xa0	-20°C	1 month

\t\t\t\t\t\t\t\t\t\t溶解性数据\t\t\tIn Vitro:\xa0\t\t\t

DMSO : 15.62 mg/mL\xa0(42.40 mM;\xa0Need ultrasonic)

\t\t\t

H₂O : < 0.1 mg/mL\xa0(insoluble)

\t\t\t
\t\t\t配制储备液\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

浓度溶剂体积质量	1 mg	5 mg	10 mg

\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

1 mM	2.7146 mL	13.5729 mL	27.1459 mL
5 mM	0.5429 mL	2.7146 mL	5.4292 mL
10 mM	0.2715 mL	1.3573 mL	2.7146 mL

\t\t\t
\t\t\t*\t\t\t

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
\t\t\t储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

\t\t\t
\t\t\tIn Vivo:\t\t\t

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照\xa0In Vitro\xa0方式配制澄清的储备液，再依次添加助溶剂：

\t\t\t

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
\t\t\t分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

\t\t\t

\t\t\t\t
• 1.\t\t\t\t

  请依序添加每种溶剂：\xa010% DMSO \xa0\xa0 40%\xa0PEG300\xa0\xa0\xa0 5%\xa0Tween-80\xa0\xa0\xa0 45% saline

  \t\t\t\t

  Solubility: ≥ 1.56 mg/mL (4.23 mM); Clear solution

  \t\t\t\t

  \xa0

  \t\t\t\t
\t\t\t\t
• 2.\t\t\t\t

  请依序添加每种溶剂：\xa050%\xa0PEG300\xa0\xa0\xa0 50% saline

  \t\t\t\t

  Solubility: 1.51 mg/mL (4.10 mM); Suspended solution; Need ultrasonic

  \t\t\t\t
\t\t\t

\t\t\t\t\t\t\t\t\t\t\t储存方式\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

Powder	-20°C	3 years
\xa0	4°C	2 years
In solvent	-80°C	6 months
\xa0	-20°C	1 month

\t\t\t\t\t\t\t\t储存方式储存方式\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

Powder	-20°C	3 years
\xa0	4°C	2 years
In solvent	-80°C	6 months
\xa0	-20°C	1 month

\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

Powder	-20°C	3 years
\xa0	4°C	2 years
In solvent	-80°C	6 months
\xa0	-20°C	1 month

\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tPowder\t\t\t\t\t\t-20°C\t\t\t\t\t\t3 years\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\xa0\t\t\t\t\t\t4°C\t\t\t\t\t\t2 years\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tIn solvent\t\t\t\t\t\t-80°C\t\t\t\t\t\t6 months\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\xa0\t\t\t\t\t\t-20°C\t\t\t\t\t\t1 month\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tPowder\t\t\t\t\t\t-20°C\t\t\t\t\t\t3 years\t\t\t\t\t\t\t\t\t\t\tPowderPowder\t\t\t\t\t\t-20°C-20°C\t\t\t\t\t\t3 years3 years\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\xa0\t\t\t\t\t\t4°C\t\t\t\t\t\t2 years\t\t\t\t\t\t\t\t\t\t\t\xa0\xa0\t\t\t\t\t\t4°C4°C\t\t\t\t\t\t2 years2 years\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\tIn solvent\t\t\t\t\t\t-80°C\t\t\t\t\t\t6 months\t\t\t\t\t\t\t\t\t\t\tIn solventIn solvent\t\t\t\t\t\t-80°C-80°C\t\t\t\t\t\t6 months6 months\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\xa0\t\t\t\t\t\t-20°C\t\t\t\t\t\t1 month\t\t\t\t\t\t\t\t\t\t\t\xa0\xa0\t\t\t\t\t\t-20°C-20°C\t\t\t\t\t\t1 month1 month\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t溶解性数据\t\t\tIn Vitro:\xa0\t\t\t

DMSO : 15.62 mg/mL\xa0(42.40 mM;\xa0Need ultrasonic)

\t\t\t

H₂O : < 0.1 mg/mL\xa0(insoluble)

\t\t\t
\t\t\t配制储备液\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

浓度溶剂体积质量	1 mg	5 mg	10 mg

\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

1 mM	2.7146 mL	13.5729 mL	27.1459 mL
5 mM	0.5429 mL	2.7146 mL	5.4292 mL
10 mM	0.2715 mL	1.3573 mL	2.7146 mL

\t\t\t
\t\t\t*\t\t\t

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
\t\t\t储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

\t\t\t
\t\t\tIn Vivo:\t\t\t

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照\xa0In Vitro\xa0方式配制澄清的储备液，再依次添加助溶剂：

\t\t\t

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
\t\t\t分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

\t\t\t

\t\t\t\t
• 1.\t\t\t\t

  请依序添加每种溶剂：\xa010% DMSO \xa0\xa0 40%\xa0PEG300\xa0\xa0\xa0 5%\xa0Tween-80\xa0\xa0\xa0 45% saline

  \t\t\t\t

  Solubility: ≥ 1.56 mg/mL (4.23 mM); Clear solution

  \t\t\t\t

  \xa0

  \t\t\t\t
\t\t\t\t
• 2.\t\t\t\t

  请依序添加每种溶剂：\xa050%\xa0PEG300\xa0\xa0\xa0 50% saline

  \t\t\t\t

  Solubility: 1.51 mg/mL (4.10 mM); Suspended solution; Need ultrasonic

  \t\t\t\t
\t\t\t

\t\t\t\t\t\t\t\t溶解性数据溶解性数据\t\t\tIn Vitro:\xa0\t\t\t

DMSO : 15.62 mg/mL\xa0(42.40 mM;\xa0Need ultrasonic)

\t\t\t

H₂O : < 0.1 mg/mL\xa0(insoluble)

\t\t\t
\t\t\t配制储备液\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

浓度溶剂体积质量	1 mg	5 mg	10 mg

\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

1 mM	2.7146 mL	13.5729 mL	27.1459 mL
5 mM	0.5429 mL	2.7146 mL	5.4292 mL
10 mM	0.2715 mL	1.3573 mL	2.7146 mL

\t\t\t
\t\t\t*\t\t\t

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
\t\t\t储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

\t\t\t
\t\t\tIn Vivo:\t\t\t

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照\xa0In Vitro\xa0方式配制澄清的储备液，再依次添加助溶剂：

\t\t\t

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
\t\t\t分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

\t\t\t

\t\t\t\t
• 1.\t\t\t\t

  请依序添加每种溶剂：\xa010% DMSO \xa0\xa0 40%\xa0PEG300\xa0\xa0\xa0 5%\xa0Tween-80\xa0\xa0\xa0 45% saline

  \t\t\t\t

  Solubility: ≥ 1.56 mg/mL (4.23 mM); Clear solution

  \t\t\t\t

  \xa0

  \t\t\t\t
\t\t\t\t
• 2.\t\t\t\t

  请依序添加每种溶剂：\xa050%\xa0PEG300\xa0\xa0\xa0 50% saline

  \t\t\t\t

  Solubility: 1.51 mg/mL (4.10 mM); Suspended solution; Need ultrasonic

  \t\t\t\t
\t\t\t

\t\t\tIn Vitro:\xa0\t\t\t

DMSO : 15.62 mg/mL\xa0(42.40 mM;\xa0Need ultrasonic)

DMSO : 15.62 mg/mLDMSO : 15.62 mg/mL\xa0(42.40 mM42.40 mM;;\xa0Need ultrasonic)\t\t\t

H₂O : < 0.1 mg/mL\xa0(insoluble)

H₂O : < 0.1 mg/mLH₂2O : < 0.1 mg/mL\xa0(insoluble)\t\t\t
\t\t\t配制储备液\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

浓度溶剂体积质量	1 mg	5 mg	10 mg

\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t浓度溶剂体积质量\t\t\t\t\t\t1 mg\t\t\t\t\t\t5 mg\t\t\t\t\t\t10 mg\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t浓度溶剂体积质量\t\t\t\t\t\t1 mg\t\t\t\t\t\t5 mg\t\t\t\t\t\t10 mg\t\t\t\t\t\t\t\t\t\t\t浓度溶剂体积质量浓度溶剂体积质量\t\t\t\t\t\t1 mg1 mg\t\t\t\t\t\t5 mg5 mg\t\t\t\t\t\t10 mg10 mg\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t

1 mM	2.7146 mL	13.5729 mL	27.1459 mL
5 mM	0.5429 mL	2.7146 mL	5.4292 mL
10 mM	0.2715 mL	1.3573 mL	2.7146 mL

\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1 mM\t\t\t\t\t\t2.7146 mL\t\t\t\t\t\t13.5729 mL\t\t\t\t\t\t27.1459 mL\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t5 mM\t\t\t\t\t\t0.5429 mL\t\t\t\t\t\t2.7146 mL\t\t\t\t\t\t5.4292 mL\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t10 mM\t\t\t\t\t\t0.2715 mL\t\t\t\t\t\t1.3573 mL\t\t\t\t\t\t2.7146 mL\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t1 mM\t\t\t\t\t\t2.7146 mL\t\t\t\t\t\t13.5729 mL\t\t\t\t\t\t27.1459 mL\t\t\t\t\t\t\t\t\t\t\t1 mM1 mM\t\t\t\t\t\t2.7146 mL2.7146 mL\t\t\t\t\t\t13.5729 mL13.5729 mL\t\t\t\t\t\t27.1459 mL27.1459 mL\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t5 mM\t\t\t\t\t\t0.5429 mL\t\t\t\t\t\t2.7146 mL\t\t\t\t\t\t5.4292 mL\t\t\t\t\t\t\t\t\t\t\t5 mM5 mM\t\t\t\t\t\t0.5429 mL0.5429 mL\t\t\t\t\t\t2.7146 mL2.7146 mL\t\t\t\t\t\t5.4292 mL5.4292 mL\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t10 mM\t\t\t\t\t\t0.2715 mL\t\t\t\t\t\t1.3573 mL\t\t\t\t\t\t2.7146 mL\t\t\t\t\t\t\t\t\t\t\t10 mM10 mM\t\t\t\t\t\t0.2715 mL0.2715 mL\t\t\t\t\t\t1.3573 mL1.3573 mL\t\t\t\t\t\t2.7146 mL2.7146 mL\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\t\t\t*\t\t\t

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
\t\t\t储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效请分装保存，避免反复冻融造成的产品失效。
\t\t\t储备液的保存方式和期限：储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。\t\t\t
\t\t\tIn Vivo:\t\t\t

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照\xa0In Vitro\xa0方式配制澄清的储备液，再依次添加助溶剂：

请根据您的实验动物和给药方式实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照\xa0In VitroIn Vitro\xa0方式配制澄清的储备液，再依次添加助溶剂：\t\t\t

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
\t\t\t分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用建议您现用现配，当天使用； 以下溶剂前显示的百
\t\t\t分比是指该溶剂在您配制终溶液中的体积占比该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶加热和/或超声的方式助溶\t\t\t

\t\t\t\t
• 1.\t\t\t\t

  请依序添加每种溶剂：\xa010% DMSO \xa0\xa0 40%\xa0PEG300\xa0\xa0\xa0 5%\xa0Tween-80\xa0\xa0\xa0 45% saline

  \t\t\t\t

  Solubility: ≥ 1.56 mg/mL (4.23 mM); Clear solution

  \t\t\t\t

  \xa0

  \t\t\t\t
\t\t\t\t
• 2.\t\t\t\t

  请依序添加每种溶剂：\xa050%\xa0PEG300\xa0\xa0\xa0 50% saline

  \t\t\t\t

  Solubility: 1.51 mg/mL (4.10 mM); Suspended solution; Need ultrasonic

  \t\t\t\t
\t\t\t

\t\t\t\t

1.\t\t\t\t

请依序添加每种溶剂：\xa010% DMSO \xa0\xa0 40%\xa0PEG300\xa0\xa0\xa0 5%\xa0Tween-80\xa0\xa0\xa0 45% saline

\t\t\t\t

Solubility: ≥ 1.56 mg/mL (4.23 mM); Clear solution

\t\t\t\t

\xa0

\t\t\t\t

1.\t\t\t\t

请依序添加每种溶剂：\xa010% DMSO \xa0\xa0 40%\xa0PEG300\xa0\xa0\xa0 5%\xa0Tween-80\xa0\xa0\xa0 45% saline

请依序添加每种溶剂：\xa010% DMSO \xa0\xa0 40%\xa0PEG300PEG300\xa0\xa0\xa0 5%\xa0Tween-80Tween-80\xa0\xa0\xa0 45% saline\t\t\t\t

Solubility: ≥ 1.56 mg/mL (4.23 mM); Clear solution

Solubility: ≥ 1.56 mg/mL (4.23 mM); Clear solution\t\t\t\t

\xa0

\xa0\t\t\t\t\t\t\t\t

2.\t\t\t\t

请依序添加每种溶剂：\xa050%\xa0PEG300\xa0\xa0\xa0 50% saline

\t\t\t\t

Solubility: 1.51 mg/mL (4.10 mM); Suspended solution; Need ultrasonic

\t\t\t\t

2.\t\t\t\t

请依序添加每种溶剂：\xa050%\xa0PEG300\xa0\xa0\xa0 50% saline

请依序添加每种溶剂：\xa050%\xa0PEG300PEG300\xa0\xa0\xa0 50% saline\t\t\t\t

Solubility: 1.51 mg/mL (4.10 mM); Suspended solution; Need ultrasonic

Solubility: 1.51 mg/mL (4.10 mM); Suspended solution; Need ultrasonic\t\t\t\t\t\t\t\t\t\t\t\t\t


\xa0\t\t\t\t\t\t\t\t\t\t\t\t

参考文献

\t\t\t \t\t\t\t \t\t\t\t [1].\xa0Zhu Jf, et al. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PLoS One. 2011;6(8):e23720. \t\t\t\t [2].\xa0Yao D, et al. Icaritin, an exogenous phytomolecule, enhances osteogenesis but not angiogenesis--an in vitro efficacy study. PLoS One. 2012;7(8):e41264. \t\t\t\t [3].\xa0Guo Y, et al. An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol. 2011 May 11;658(2-3):114-22. \t\t\t\t \t\t\t \t\t\t

\t\t\t\t\t\t参考文献\t\t\t\t\t\t

\t\t\t\t
• \t\t\t\t

  [1].\xa0Zhu Jf, et al. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PLoS One. 2011;6(8):e23720.

  \t\t\t\t

  [2].\xa0Yao D, et al. Icaritin, an exogenous phytomolecule, enhances osteogenesis but not angiogenesis--an in vitro efficacy study. PLoS One. 2012;7(8):e41264.

  \t\t\t\t

  [3].\xa0Guo Y, et al. An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol. 2011 May 11;658(2-3):114-22.

  \t\t\t\t
\t\t\t

\t\t\t\t\t\t\t\t\t\t\t参考文献\t\t\t\t\t\t

\t\t\t\t
• \t\t\t\t

  [1].\xa0Zhu Jf, et al. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PLoS One. 2011;6(8):e23720.

  \t\t\t\t

  [2].\xa0Yao D, et al. Icaritin, an exogenous phytomolecule, enhances osteogenesis but not angiogenesis--an in vitro efficacy study. PLoS One. 2012;7(8):e41264.

  \t\t\t\t

  [3].\xa0Guo Y, et al. An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol. 2011 May 11;658(2-3):114-22.

  \t\t\t\t
\t\t\t

\t\t\t\t\t\t\t\t参考文献参考文献\t\t\t\t\t\t

\t\t\t\t
• \t\t\t\t

  [1].\xa0Zhu Jf, et al. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PLoS One. 2011;6(8):e23720.

  \t\t\t\t

  [2].\xa0Yao D, et al. Icaritin, an exogenous phytomolecule, enhances osteogenesis but not angiogenesis--an in vitro efficacy study. PLoS One. 2012;7(8):e41264.

  \t\t\t\t

  [3].\xa0Guo Y, et al. An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol. 2011 May 11;658(2-3):114-22.

  \t\t\t\t
\t\t\t

\t\t\t\t\t\t

\t\t\t\t
• \t\t\t\t

  [1].\xa0Zhu Jf, et al. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PLoS One. 2011;6(8):e23720.

  \t\t\t\t

  [2].\xa0Yao D, et al. Icaritin, an exogenous phytomolecule, enhances osteogenesis but not angiogenesis--an in vitro efficacy study. PLoS One. 2012;7(8):e41264.

  \t\t\t\t

  [3].\xa0Guo Y, et al. An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol. 2011 May 11;658(2-3):114-22.

  \t\t\t\t
\t\t\t

\t\t\t\t

\t\t\t\t

[1].\xa0Zhu Jf, et al. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PLoS One. 2011;6(8):e23720.

\t\t\t\t

[2].\xa0Yao D, et al. Icaritin, an exogenous phytomolecule, enhances osteogenesis but not angiogenesis--an in vitro efficacy study. PLoS One. 2012;7(8):e41264.

\t\t\t\t

[3].\xa0Guo Y, et al. An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol. 2011 May 11;658(2-3):114-22.

\t\t\t\t

\t\t\t\t

[1].\xa0Zhu Jf, et al. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PLoS One. 2011;6(8):e23720.

[1].\xa0Zhu Jf, et al. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PLoS One. 2011;6(8):e23720.Zhu Jf, et al. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings. PLoS One. 2011;6(8):e23720.\t\t\t\t

[2].\xa0Yao D, et al. Icaritin, an exogenous phytomolecule, enhances osteogenesis but not angiogenesis--an in vitro efficacy study. PLoS One. 2012;7(8):e41264.

[2].\xa0Yao D, et al. Icaritin, an exogenous phytomolecule, enhances osteogenesis but not angiogenesis--an in vitro efficacy study. PLoS One. 2012;7(8):e41264.Yao D, et al. Icaritin, an exogenous phytomolecule, enhances osteogenesis but not angiogenesis--an in vitro efficacy study. PLoS One. 2012;7(8):e41264.\t\t\t\t

[3].\xa0Guo Y, et al. An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol. 2011 May 11;658(2-3):114-22.

[3].\xa0Guo Y, et al. An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol. 2011 May 11;658(2-3):114-22.Guo Y, et al. An anticancer agent icaritin induces sustained activation of the extracellular signal-regulated kinase (ERK) pathway and inhibits growth of breast cancer cells. Eur J Pharmacol. 2011 May 11;658(2-3):114-22.